Dark Blue Therapeutics Ltd is a biotechnology company based in Oxford, UK, founded in 2020 as a spinout from the University of Oxford. The company specializes in precision oncology, developing first-in-class small-molecule therapies that target novel cancer vulnerabilities, including protein degraders.
Its lead candidate, DBT-3757, is a targeted protein degrader of MLLT1/3 proteins, advancing through IND-enabling studies for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The preclinical program demonstrates promising anti-cancer activity and potential as a single-agent therapy.
In January 2026, Dark Blue Therapeutics was acquired by Amgen in a deal valued at up to $840 million, integrating its pipeline into Amgen's oncology research efforts to address unmet needs in difficult-to-treat cancers like AML.
VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
Successor returns July 1 as EVP and assumes CFO duties Sept 1; outgoing CFO stays through Jan 2027 to aid transition. Successor has 30+ yrs finance leadership, ex‑CFO at Galderma, Shire, Sulzer.
Expands Puerto Rico biologics facility to boost U.S. production, deploy next‑gen technologies, support workforce development and construction jobs, and strengthen medicine supply‑chain resilience
Reese retires June 30, 2026. Effective June 1, leadership reshuffle: James Bradner named EVP R&D, AI & Data; Sean Bruich CTO; Murdo Gordon EVP Global Markets & Policy; Paul Burton remains CMO.
VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.
